Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 25.48 -2.93% -0.77
APLS closed down 2.93 percent on Thursday, September 19, 2019, on 1.73 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical APLS trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -2.93%
Outside Day Range Expansion -2.93%
Lower Bollinger Band Touch Weakness -2.93%
Oversold Stochastic Weakness -2.93%
MACD Bearish Centerline Cross Bearish -2.04%
Calm After Storm Range Contraction -2.04%

Older signals for APLS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Chronic Obstructive Pulmonary Disease Autoimmune And Inflammatory Diseases Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh
Is APLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 33.18
52 Week Low 11.45
Average Volume 451,004
200-Day Moving Average 20.6721
50-Day Moving Average 28.1208
20-Day Moving Average 28.762
10-Day Moving Average 28.605
Average True Range 1.6927
ADX 23.28
+DI 17.389
-DI 31.7992
Chandelier Exit (Long, 3 ATRs ) 28.1019
Chandelier Exit (Short, 3 ATRs ) 30.2181
Upper Bollinger Band 32.6898
Lower Bollinger Band 24.8342
Percent B (%b) 0.08
BandWidth 27.312426
MACD Line -0.4197
MACD Signal Line 0.194
MACD Histogram -0.6137
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.75
Resistance 3 (R3) 27.98 27.47 27.37
Resistance 2 (R2) 27.47 26.89 27.35 27.24
Resistance 1 (R1) 26.47 26.53 26.22 26.24 27.12
Pivot Point 25.96 25.96 25.83 25.84 25.96
Support 1 (S1) 24.96 25.38 24.71 24.73 23.84
Support 2 (S2) 24.45 25.02 24.33 23.72
Support 3 (S3) 23.45 24.45 23.59
Support 4 (S4) 23.22